LAMPRENE Soft gelatin capsule Ref.[50443] Active ingredients: Chlofazimine

Source: Health Products Regulatory Authority (ZA)  Revision Year: 2022  Publisher: Novartis South Africa (Pty) Ltd, Magwa Crescent West, Jukskei View, Waterfall City, Johannesburg, 2090

Product name and form

LAMPRENE 50 mg Soft Gelatin Capsules.

LAMPRENE 100mg Soft Gelatin Capsules.

Pharmaceutical Form

LAMPRENE 50 mg soft gelatin capsule: Spherical, brown, opaque soft gelatin capsules with no imprint on the capsules. Diameter approximately 7,2 mm.

LAMPRENE 100 mg soft gelatin capsule: Brown, opaque, oblong, soft gelatin capsules. One side carries the imprint “GEIGY”, the other side carries imprint “GM” in white. Diameter approximately 6,5 mm.

Qualitative and quantitative composition

Active ingredient:

LAMPRENE 50 mg Soft Gelatin Capsules: Each capsule contains 50 mg clofazimine present as a microcrystalline suspension in an oil-wax base.

LAMPRENE 100 mg Soft Gelatin Capsules: Each capsule contains 100 mg micronised clofazimine suspended in an oil-wax base.

Sugar free.

For full list of excipients, see section 6.1.

Active Ingredient Description
Chlofazimine

Clofazimine is an antimycobacterial drug. Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA.

List of Excipients

Capsule content:

Butylated hydroxytoluene
Citric acid (anhydrous)
Propylene glycol
Rapeseed oil (refined)
Lecithin (E322)
Beeswax (yellow)
Soybean oil (hydrogenated)
Soya-bean oils (partially hydrogenated)

Capsule shell:

Ethyl parahydroxybenzoate sodium
Propyl parahydroxybenzoate sodium
Ethylvanillin
Gelatin
Glycerol 85%
Black iron oxide (E172)
Red iron oxide (E172)
P-methoxy acetophenone

Pack sizes and marketing

LAMPRENE 50/100 mg soft gelatin capsules are either packaged in white to off-white high density polyethylene (HDPE) bottles with a HDPE screw cap with a yellow tamper proof ring, further packaged in paper board carton or can be packaged in low density polyethylene (LDPE) bags inserted in high density polyethylene (HDPE) bottle with a HDPE screw cap.

Kindly note that not all strengths may be marketed.

Marketing authorization holder

Novartis South Africa (Pty) Ltd, Magwa Crescent West, Jukskei View, Waterfall City, Johannesburg, 2090

Marketing authorization dates and numbers

LAMPRENE 50 mg soft gelatin capsules: 53/20.2.4/0472
LAMPRENE 100 mg soft gelatin capsules: B/20.2.4/108

19 April 2018

Drugs

Drug Countries
LAMPRENE Estonia, France, Malta, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.